Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 339

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 339
---
 services to a customer.

In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract - in respect of which revenue will be recognized separately for each component.

The following assumptions were taken into account, as part of the revenue recognition process:

  Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the t...  

  Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual pro...  

For more information, see Notes 16 and 17.

  Research and development expenses  

Research expenses are charged to profit or loss as incurred. As of December 31, 2024, the Company has not yet capitalized development expenses.

  Share-based payments  

The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company’s share price).

Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.

  Loss per share  

  Basic  

The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares, including pre-funded warrants, outstanding during the year.

  Diluted  

The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company’s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2022, 2023 and 2024, as their effect would have been anti-dilutive.

The calculation of diluted loss per share for the years ended December 31, 2022, 2023 and 2024 does not include347,113,402,585,109,579and566,